Accelerated Bookbuild Offering
Hansa Biopharma
Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Hansa Biopharma’s Capital Increase of SEK 1.11 billion
Transaction highlights
- Capital increase of 4,447,345 shares, representing c. 9.9% of the issued share capital of Hansa Biopharma after the launch, at a price of SEK 250.00 per share, representing a discount of 8.5% to the last closing price
- The transaction was launched on the back of the positive CHMP opinion for Hansa Biopharma’s lead product candidate imlifidase in kidney transplantation in highly sensitized patients, as well as a partnership announcement with Sarepta Therapeutics to use Hansa’s unique IgG antibody-cleaving enzyme technology alongside gene therapy in select indications
- Gross proceeds amounted to SEK 1.11 billion/ USD 121 million, which will be used to continue the development and expansion of the Company’s R&D pipeline as well as to fund the potential launch and commercialization of imlifidase in kidney transplantation
- The share issue was multiple times covered with significant support from existing shareholders and wall-crossed accounts, including Redmile Group, Consonance Capital, HBM Healthcare Investments and Fonden TIN Ny Teknik
- Kempen & Co has been supporting the Company in its outreach to specialist investors since 2018
- Since the beginning of 2020, Kempen & Co has already executed 13 transactions for European life sciences companies.
Company description
Hansa Biopharma is a clinical-stage biotechnology company leveraging its proprietary IgG antibody- cleaving enzyme technology platform to develop treatments for enabling transplantations, rare autoimmune conditions, transplant rejection and cancer. On 25 June, the Company announced a positive CHMP opinion for its lead product candidate imlifidase, which recommends conditional approval of imlifidase for kidney transplantation in highly sensitized patients in Europe. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. On 02 July, the Company announced a partnership with Sarepta Therapeutics, a leader within gene therapy focusing on muscular dystrophies, allowing them to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today are not eligible for these breakthrough therapies due to pre-existing neutralising antibodies. As part of this partnership, Hansa will receive a USD 10 million upfront payment and potential development, regulatory and sales milestone payments up to USD 397.5 million, as well as mid-teens tiered royalties on Sarepta’s gene therapy sales. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the United States.Relevant transactions Kempen & Co Life Sciences & Healthcare
Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Co-Manager in the USD 49.0 million US Public Offering by Centogene
- Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
- Co-Manager in the USD 600 million US Public Offering by Ascendis Pharma
- Financial advisor in the USD 253 million Immatics’ business combination with Arya Sciences Acquisition Corp.Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
- Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
- Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
- Co-Manager in the USD 862 million Global Offering by argenx
- Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
- Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
- Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
- Lead Manager in the USD 557 million Global Offering by argenx
- Co-Manager in the USD 79.2 million US Public Offering by Merus
- Co-Manager in the USD 57.5 million Capital Increase by ProQR
- Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
- Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
- Co-Manager in the USD 20.0 million Global Offering of Celyad
- Co-Manager in the USD 582 million NASDAQ IPO of Genmab
Contact
Read more on:
Transactions
No transactions found
Placing
Capital Increase
US Public Offering
Sale to
Portfolio company of
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Mandatory Convertible Bond Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Capital increase
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
on Nasdaq
Initial Public Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Capital increase
Private Placement
US Public Offering
Initial Public Offering
US Public Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
Debt financing
US Public Offering
US Public Offering
Green Revolving Credit Facility
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase 
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
US Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
Rights issue
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Fundraise
Accelerated bookbuild offering
Public offer by German ADLER Real Estate
for Israeli
Public offer by German Vonovia
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
Accelerated bookbuild offering
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue